 Ovarian Neoplasms
"Ovarian Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
| Descriptor ID |
D010051
|
| MeSH Number(s) |
C04.588.322.455 C13.351.500.056.630.705 C13.351.937.418.685 C19.344.410 C19.391.630.705
|
| Concept/Terms |
Ovarian Neoplasms- Ovarian Neoplasms
- Neoplasm, Ovarian
- Ovarian Neoplasm
- Ovary Neoplasms
- Neoplasm, Ovary
- Neoplasms, Ovary
- Ovary Neoplasm
- Neoplasms, Ovarian
Ovary Cancer- Ovary Cancer
- Cancer, Ovary
- Cancers, Ovary
- Ovary Cancers
- Ovarian Cancer
- Cancer, Ovarian
- Cancers, Ovarian
- Ovarian Cancers
- Cancer of Ovary
- Cancer of the Ovary
|
Below are MeSH descriptors whose meaning is more general than "Ovarian Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Ovarian Neoplasms".
This graph shows the total number of publications written about "Ovarian Neoplasms" by people in this website by year, and whether "Ovarian Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 4 | 3 | 7 | | 1997 | 1 | 0 | 1 | | 1998 | 3 | 0 | 3 | | 1999 | 1 | 1 | 2 | | 2000 | 2 | 0 | 2 | | 2002 | 0 | 2 | 2 | | 2003 | 3 | 1 | 4 | | 2004 | 3 | 1 | 4 | | 2005 | 4 | 1 | 5 | | 2006 | 1 | 1 | 2 | | 2007 | 8 | 0 | 8 | | 2008 | 9 | 1 | 10 | | 2009 | 3 | 1 | 4 | | 2010 | 7 | 5 | 12 | | 2011 | 15 | 2 | 17 | | 2012 | 12 | 1 | 13 | | 2013 | 12 | 3 | 15 | | 2014 | 11 | 1 | 12 | | 2015 | 21 | 2 | 23 | | 2016 | 27 | 2 | 29 | | 2017 | 14 | 0 | 14 | | 2018 | 12 | 5 | 17 | | 2019 | 22 | 0 | 22 | | 2020 | 30 | 1 | 31 | | 2021 | 22 | 2 | 24 | | 2022 | 23 | 1 | 24 | | 2023 | 20 | 0 | 20 | | 2024 | 19 | 3 | 22 | | 2025 | 15 | 0 | 15 | | 2026 | 12 | 0 | 12 |
To return to the timeline, click here.
Below are the most recent publications written about "Ovarian Neoplasms" by people in Profiles.
-
Smith LP, Brubaker LW, Wolsky RJ. It Does Exist! Diagnosis and Management of Thyroid Carcinomas Originating in Struma Ovarii. Clin Lab Med. 2026 Sep; 46(3):501-516.
-
Cole AR, Buj R, Uboveja A, Levasseur E, Tom A, Wang H, Kedziora KM, Chatoff A, Huacachino AA, Marcinkiewicz MM, Amalric A, Yang B, Tangudu NK, Noonan E, Danielson J, Naruse M, Elhaw AT, White S, Li D, Wallace CT, Keeney F, Lazure F, Elishaev E, Borho L, Townsend HA, Dowell RD, Clauset A, Jazwinska DE, Laird MS, Atiya H, Dangaj D, Coffman LG, Tseng G, Oesterreich S, Kossenkov A, Liu Q, Gomes AP, Gurkar AU, Schopfer FJ, Modugno F, Watkins SC, Zervantonakis IK, Bitler BG, Stallaert W, Hempel N, Snyder NW, Aird KM. The chemotherapy-induced senescence-associated secretome promotes cell detachment and metastatic dissemination through metabolic reprogramming. Nat Aging. 2026 Aug; 6(8):1647-1666.
-
Rich BS, Fishbein JS, Purcell LN, Murphy JT, Castle SL, Ghanbari N, Zohrabian A, Lautz TB, Kacey W, Post G, Thangarajah H, West E, Roach JP, Corkum KS, Perry T, Piché N, Roy M, Stafman LL, Dixon SM, Glithero KJ, Pittman ME, Çeliker MY, Grant CN, Sharf T, Tracy ET, Wachsmuth LP, Rustad A, Newman EA, Williams K, Wunker CM, Glick RD, Dasgupta R, Wilson S, Vore E, Cromeens BP, Turk F, Shaffiey SA, Alkhoury F, Goyal J, Brown EG, Seemann NM, Wilson CA, Davidson J, Polites SF, Parrish MT, Cameron DB, Stetson A, Gold RM, Aldrink JH, Mansfield SA, Srivatsa S, Christison-Lagay E, Rehman SU, Fialkowski EA, Selesner L, Larsen A, Le HD, Tracy SA, Ahmed T, Dimmer A, Malek MM, Campwala I, Colangelo A, Rothstein DH, Nchinda NN, Mattei P, Jain S, Hwang R, Craig BT, Lal DR, Abrebese E, Rhee DS, Chidiac C, Peters M, Boehmer C, Billmire DF. Immature teratoma of the ovary in children and adolescents: A multi-institutional study of characteristics and management. Gynecol Oncol. 2026 Aug; 211:115-124.
-
Rich BS, Fishbein JS, Purcell LN, Murphy JT, Castle SL, Ghanbari N, Zohrabian A, Lautz TB, Kacey W, Post G, Thangarajah H, West E, Roach JP, Corkum KS, Perry T, Piché N, Roy M, Stafman LL, Dixon SM, Glithero KJ, Pittman ME, Çeliker MY, Grant CN, Sharf T, Tracy ET, Wachsmuth LP, Rustad A, Newman EA, Williams K, Wunker CM, Glick RD, Dasgupta R, Wilson S, Vore E, Cromeens BP, Turk F, Shaffiey SA, Alkhoury F, Goyal J, Brown EG, Seemann NM, Wilson CA, Davidson J, Polites SF, Parrish MT, Cameron DB, Stetson A, Gold RM, Aldrink JH, Mansfield SA, Srivatsa S, Christison-Lagay E, Rehman SU, Fialkowski EA, Selesner L, Larsen A, Le HD, Tracy SA, Ahmed T, Dimmer A, Malek MM, Campwala I, Colangelo A, Rothstein DH, Nchinda NN, Mattei P, Jain S, Hwang R, Craig BT, Lal DR, Abrebese E, Rhee DS, Chidiac C, Peters M, Boehmer C, Billmire DF. Immature teratoma of the ovary with microscopic yolk sac tumor in children and adolescents: A multi-institutional study. Gynecol Oncol. 2026 Aug; 211:125-131.
-
Lu KH, Norquist BM, Chisholm GB, Peterson CB, Long Roche KC, Bakkum-Gamez JN, Romero IL, Feltmate C, Levine DA, Kim S, Hagemann AR, Carter J, Hickey M, Crase J, Gavin K, Polinsky D, D'Andrea AD, Nebgen DR, Swisher EM. Patient-Centered Approach to Surgical Prevention of Ovarian Cancer: A Nonrandomized Clinical Trial. JAMA Netw Open. 2026 Jul 01; 9(7):e2622026.
-
Spaur M, Hurwitz LM, Medgyesi DN, Keil AP, Beane Freeman LE, Fisher JA, Madrigal JM, Ammons S, Spielfogel ES, Bangia K, Albert PS, Sanchez TR, Lacey JV, Jones RR, Ward MH. Exposures to Drinking Water Contaminants in Community Water Systems and Risk of Ovarian Cancer in the California Teachers Study Cohort. Environ Health Perspect. 2026 08 04; 134(4):452-464.
-
Ehimiaghe E, Nicklawsky A, Wang S, Torkko KC, Mastryoannis SA, Bonetto A, Novinger LJ. Prevalence of ovarian cancer cachexia in patients undergoing cytoreductive surgery at the University of Colorado between 2014-2024. J Ovarian Res. 2026 Apr 11; 19(1).
-
Arch JJ, Uno H, Poort H, Slivjak E, Nealis MS, Park H, Wang I, Genung SR, Cronin A, Andorsky DJ, Havrilesky LJ, Penson RT, Mazina V, Widick P, Lefkowits C, Wright AA. Randomized clinical trial of an Acceptance and Commitment Therapy telehealth intervention ('REVITALIZE') to reduce fatigue interference in women with advanced ovarian cancer on PARP inhibitors: study protocol. BMC Cancer. 2026 Apr 02; 26(1).
-
Chen XL, Tharp KM, Ojalill M, Ozmadenci D, Boyer A, Haanen TJ, Lawson C, Lee HJ, Xia M, Tahon E, Zhang Y, Minor C, Khan SU, Anderson CC, Nemkov T, Rose M, Estrada MV, Molinolo AA, Warren E, Penalosa P, Eskander RN, McHale MT, Wang SE, Connolly DC, Fisch KM, Stupack DG, Schlaepfer DD. FAK inhibition in ovarian cancer releases omega-3 fatty acids to program CXCL13-producing anti-tumor resident peritoneal macrophages. Cell Rep. 2026 Mar 24; 45(3):117009.
-
Hollis RL, Miller A, Lankes HA, Wong KK, Rodgers W, Millan D, Carty K, Coleman RL, Moore KN, Alvarez Secord A, O'Malley DM, Chan JK, Hagemann AR, Gaillard S, Guntupalli SR, Edelson MI, Rose PG, Dorigo O, Banerjee S, Ewing A, Churchman M, Sood AK, Herrington CS, Gourley C, Gershenson DM. Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma. Clin Cancer Res. 2026 Feb 17; 32(4):724-734.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|